Ruxolitinib

CAS No.	941678-49-5	Cat. No.	BCP02424
Name	Ruxolitinib
Synonyms	INCB 018424;INCB018424;INCB-018424; INC 424; INC424; INC-424; INCB18424; INCB 18424; INCB-18424;
Formula	C17H18N6	M. Wt	306.36

Description	Ruxolitinib is an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.
Related Products	1092939-17-7（Ruxolitinib phosphate）
Pathways	Angiogenesis/Protein Tyrosine Kinase Jak/Stat Pathway Wnt/Stem Cell Epigenetics
Targets	JAK

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.